未知生产厂商
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry. A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry. A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
